[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352172-105":59,"doc-detail-352172-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pir-26681-suppresses-ovarian-cancer-progression-by-enhancing-mettl3mettl14-mediated-m6a-modification-of-fbxo16-and-impairing-dna-repair-via-morf4l1-degradation","piR-26681 suppresses ovarian cancer progression by enhancing METTL3/METTL14-mediated m6A modification of FBXO16 and impairing DNA repair via MORF4L1 degradation","","Survival rates for ovarian cancer decline sharply at late stages due to late diagnosis, and although PARP inhibitors benefit homologous recombination-deficient tumors, their impact on homologous recombination-proficient disease remains limited. piR-26681 was screened in early- and advanced-stage tissues and tested in ovarian cancer cells, xenografts, and patient-derived organoids. piR-26681 promotes METTL3/METTL14 interactions, stabilizes m6A methylation, increases FBXO16 via IGF2BP2, degrades MORF4L1, impairs HR repair, accumulates DNA damage, and sensitizes tumors to niraparib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pir-26681-suppresses-ovarian-cancer-progression-by-enhancing-mettl3mettl14-mediated-m6a-modification-of-fbxo16-and-impairing-dna-repair-via-morf4l1-degradation/352172/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pir-26681-suppresses-ovarian-cancer-progression-by-enhancing-mettl3mettl14-mediated-m6a-modification-of-fbxo16-and-impairing-dna-repair-via-morf4l1-degradation/352172.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is piR-26681 and why is it studied in ovarian cancer?","Question",{"text":112,"@type":113},"piR-26681 is a PIWI-interacting RNA screened from ovarian cancer tissues. It is significantly downregulated in advanced-stage ovarian cancer and linked to favorable prognosis, making it a candidate regulator of tumor progression and therapy response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does piR-26681 affect METTL3/METTL14 and m6A methylation?",{"text":117,"@type":113},"piR-26681 directly interacts with METTL3 and METTL14, enhances their interaction, reduces their ubiquitination, and increases their protein stability. This stabilization increases global m6A methylation in ovarian cancer cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the piR-26681 pathway impair DNA repair and sensitize to niraparib?",{"text":121,"@type":113},"Increased m6A modification stabilizes FBXO16 mRNA via the m6A reader IGF2BP2, raising FBXO16 expression. FBXO16 ubiquitinates and promotes MORF4L1 degradation, leading to loss of homologous recombination repair, greater DNA damage accumulation, and sensitization to the PARP inhibitor niraparib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352172,1790172595,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Wang et al. Cellular & Molecular Biology Letters (2026) 31:143 [https://doi.org/10.1186/s11658-026-00969-x](https://doi.org/10.1186/s11658-026-00969-x)  \nCellular & Molecular Biology Letters  \nRESEARCH Open Access  \npiR-26681 suppresses ovarian cancer  progression by enhancing METTL3/METTL14-mediated m6A modification of FBXO16 and impairing DNA repair via MORF4L1 degradation  \nJie-Lin Wang1†, Qing-Hua Wu1†, Jing Yuan1, Hai-Juan Bao 1, Xiang-Chun Huang1, Jia-Chen Cheng1, Yang Zhao2 and Shuo Chen1*  \n†Jie-Lin Wang and Qing-Hua Wu have contributed equally to this work.  \n*Correspondence:  \nShuo Chen[chenshuo077003@163.com](chenshuo077003@163.com)[ ](chenshuo077003@163.com)1Department of Obstetricsand Gynecology, Department of Gynecologic Oncology Research Office, Guangzhou Key Laboratory of Targeted Therapy for Gynecologic Oncology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, No.63 Duobao Road, Liwan District, Guangzhou, Guangdong, People’s Republic of China  \n2Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China  \nAbstract  \nBackground Survival rates for ovarian cancer drop sharply at late-stages due to late diagnosis. Although PARP inhibitors are effective in homologous recombinationdeficient (HRD) tumors, their efficacy in homologous recombination (HR)-proficient ovarian cancer remains limited, highlighting the need for novel molecular targets to inhibit tumor progression and improve patient outcomes.  \nMethods Differentially expressed piRNAs were screened using ovarian cancer tissues from early-and advanced-stage patients. Functional studies were performed in ovarian cancer cell lines, xenograft models, and patient-derived organoids. Molecular mechanisms were investigated using RNA pulldown, RNA immunoprecipitation, MeRIP-seq, ubiquitination assays, and DNA damage analyses.  \nResults We identified piR-26681 as a piRNA significantly downregulated in advancedstage ovarian cancer and associated with favorable prognosis. Functional assays demonstrated that piR-26681 suppressed ovarian cancer progression in cell lines, xenograft mouse models, and patient-derived organoids. Mechanistically, piR-26681 directly interacted with METTL3 and METTL14, enhancing their interaction, reducing their ubiquitination, and thereby increasing their protein stability. This stabilization promoted global m6A methylation in ovarian cancer cells. Increased m6A modification subsequently enhanced the stability of FBXO16 mRNA through the m6A reader IGF2BP2, leading to elevated FBXO16 expression. As an E3 ubiquitin ligase, FBXO16 further mediated the ubiquitination and degradation of MORF4L1, a key regulator of homologous recombination repair. Loss of MORF4L1 impaired HR repair, increased DNA damage accumulation, and sensitized ovarian cancer cells to the PARP inhibitor niraparib.  \nConclusions Our study identifies a novel piR-26681–METTL3/METTL14–FBXO16– MORF4L1 regulatory axis that impairs DNA repair and suppresses ovarian cancer  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by sta","cbCaiqR8Tf68mWo2","https://ap.wps.com/l/cbCaiqR8Tf68mWo2","pdf",3476871,23,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is piR-26681 and why is it studied in ovarian cancer?\",\"answer\":\"piR-26681 is a PIWI-interacting RNA screened from ovarian cancer tissues. It is significantly downregulated in advanced-stage ovarian cancer and linked to favorable prognosis, making it a candidate regulator of tumor progression and therapy response.\"},{\"question\":\"How does piR-26681 affect METTL3/METTL14 and m6A methylation?\",\"answer\":\"piR-26681 directly interacts with METTL3 and METTL14, enhances their interaction, reduces their ubiquitination, and increases their protein stability. This stabilization increases global m6A methylation in ovarian cancer cells.\"},{\"question\":\"How does the piR-26681 pathway impair DNA repair and sensitize to niraparib?\",\"answer\":\"Increased m6A modification stabilizes FBXO16 mRNA via the m6A reader IGF2BP2, raising FBXO16 expression. FBXO16 ubiquitinates and promotes MORF4L1 degradation, leading to loss of homologous recombination repair, greater DNA damage accumulation, and sensitization to the PARP inhibitor niraparib.\"}]","piR-26681 suppresses ovarian cancer progression by enhancing METTL3/METTL14-mediated m6A modification of FBXO16 and impairing DNA repair via MORF4L1 degradation | PDF",1790098072,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd02e465e47d38443a0416e4e3307388.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d91a71b111887d18ed819dc979c843f6.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de9e6d37703f3a648ea770f5dba1a718.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc243049e36d21a3733c09014cbeb89f.webp",980,1306]